Mode
Text Size
Log in / Sign up
N/A N=9 Randomized Single-blind Treatment

Daily Disposable Contact Lens Tear Film Study

Myopia

Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcome: Primary: Number of Participants With Corrected Visual Acuity of 0.0 or Better — 9; 9; 9; 9 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
delefilcon A contact lens (Device); narafilcon A contact lens (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
CIBA VISION
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Corrected Visual Acuity of 0.0 or Better
9; 9; 9; 9; 9; 9
PRIMARY
Pre-Lens Noninvasive Tear Break-Up Time
12.7; 11.3; 12.2; 13.8; 10.5; 10.1
PRIMARY
Average Tear Meniscus Height
28.0; 26.7; 26.0; 24.0; 28.7; 27.1
PRIMARY
Average Ocular Surface Temperature
35.6; 35.3; 35.2; 35.2; 35.5; 35.3
SECONDARY
Subjective Comfort
9.1; 6.8; 9.0; 6.7; 9.1; 6.3
SECONDARY
Subjective Vision
9.0; 7.8; 8.7; 7.8; 8.7; 8.0
SECONDARY
Number of Participants With Adequate Lens Fit
9; 9; 9; 9; 9; 9

Summary

The purpose of this study was to evaluate the pre-lens tear film stability of a new CE-marked daily disposable contact lens as compared to a commercially available daily disposable contact lens.

Eligibility Criteria

Inclusion Criteria

  • Be of legal age of consent and sign Informed Consent document.
  • Willing and able to wear spherical contact lenses for 16 hours.
  • Willing and able to wear spherical contact lenses within the available range of powers.
  • Best corrected spectacle visual acuity equal or better than 20/25 or 6/7.5.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Anterior segment infection, inflammation, or abnormality.
  • Any use of systemic medications for which contact lens wear could be contraindicated.
  • History of refractive surgery or irregular cornea.
  • Currently enrolled in any clinical trial.
  • Eye injury within twelve weeks prior to enrollment.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01473160). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search